Overview

• GEMORNA uses deep generative models to design coding sequences and untranslated regions for linear and circular mRNAs, aiming to improve translational capacity, durability and overall expression.
• Independent coverage reports up to 41-fold gains for luciferase in vitro and up to 15-fold increases for human EPO versus benchmarks, while the company cites up to 150-fold hEPO increases.
• Preclinical studies described higher antibody responses in mice and stronger CAR expression with enhanced anti-tumor activity in primary human T cells, according to the company’s summary.
• The platform’s outputs still require human screening, and C&EN notes potential manufacturing hurdles for large-scale production using common PCR-amplified templates.
• Raina, a Boston-based MIT spinout led by mRNA and AI researchers, published the findings in Science on Aug. 28 and is pursuing partnerships alongside an internal development pipeline after a $5.7 million angel round.